Skip to main navigation
Neoleukin Therapeutics

Investors

Press Releases

Press Releases

Date Title View
April 7, 2022 Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference
March 15, 2022 Neoleukin Therapeutics Announces Appointment of Donna Cochener as General Counsel
March 8, 2022 Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting
March 1, 2022 Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update
February 22, 2022 Neoleukin Therapeutics to Host 2021 Financial Results Conference Call and Webcast on March 1, 2022
February 3, 2022 Neoleukin Therapeutics to Present at Guggenheim Healthcare Talks 2022 Oncology Conference
January 10, 2022 Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (pembrolizumab)
January 10, 2022 Neoleukin Therapeutics Presenting at H.C. Wainwright BIOCONNECT Virtual Conference

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2

Investor Tools

  • Investor FAQs
  • Contact IR
  • Email Alerts

Neoleukin - Investors Menu (Secondary)

  • Press Releases
  • Events & Presentations
  • Financial and Filings
  • Stock Information
  • Analysts
  • Corporate Governance

Neoleukin - Investor Relations

  • About
    • Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Responsibility
    • Contact
  • Science
    • De Novo Protein Design
    • Neoleukin Platform
    • Publications
    • Collaborations & Partnerships
  • Programs
    • NL-201
    • Research
  • News
    • Press Releases
    • Events
    • In The News
    • Media Contact
  • Investors
    • Press Releases
    • Events & Presentations
    • Financial and Filings
    • Stock Information
    • Analysts
    • Corporate Governance
    • Investor FAQs
    • Contact IR
    • Email Alerts
  • Careers
    • Overview
    • Our Values
    • Our Culture
    • Job Opportunities
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Twitter
  • Neoleukin TherapeuticsHome
  • Neoleukin - Investor Relations

  • About
    • Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Responsibility
    • Contact
  • Science
    • De Novo Protein Design
    • Neoleukin Platform
    • Publications
    • Collaborations & Partnerships
  • Programs
    • NL-201
    • Research
  • News
    • Press Releases
    • Events
    • In The News
    • Media Contact
  • Investors
    • Press Releases
    • Events & Presentations
    • Financial and Filings
    • Stock Information
    • Analysts
    • Corporate Governance
    • Investor FAQs
    • Contact IR
    • Email Alerts
  • Careers
    • Overview
    • Our Values
    • Our Culture
    • Job Opportunities
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Twitter
©  Neoleukin Therapeutics, Inc. All rights reserved.
  • Twitter
  • Privacy Policy
  • Terms & Conditions